Ann: Market Update - PAT-DX1 Clinical Trial Preparation, page-212

Thought I’d post a few positives Regarding PAB. Obviously we weren’t expecting the delay but at the same time it’s understandable in the current climate that delays from the pandemic are a given no matter what field you’re in, even when your researching and developing possible life saving drugs/ therapy’s. I’m sitting nice and pretty in the red now after the news regarding the delay and recent sell off. So I thought I’d post somethings that keeps me looking towards the future with this company and blocking out the pullback and just seeing it as an opportunity to average down. I’m posting a little bit about some of our great team and just a couple of dot points. When I think about the team we have and their expertise in this area, you know that these over achievers aren’t just sitting around twiddling their thumbs .

James Campbell Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS), where, as a member of the executive team he helped transform a research-based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M.

Suzy Jones Prior to starting her own firm, Ms. Jones spent 20 years at Genentech where she served in many roles including Interim Head of Partnering, Head of Business Development, Senior Project Manager and Research Associate. She managed several products teams during this time including Rituxan, the first monoclonal antibody launched to treat cancer. Ms. Jones has very extensive networks within the pharmaceutical and biotech companies and VC community in North America.

Pamela Klein Dr. Klein previously at Genentech where, as Vice President, Development she led the development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds. After Genentech Dr. Klein was appointed to the position of Chief Medical Officer of Intellikine where she built the clinical development capability and brought multiple early compounds from laboratory to clinic prior to Intellikine before being acquired by Millennium/Takeda.

Dr Peter Ordentlich completed a PhD in Immunology at the University of Pennsylvania and a Post-Doc at the Salk Institute for Biological Studies before joining X-Ceptor Therapeutics, a discovery stage biotechnology company focused on the identification of novel therapeutics for cardiovascular and oncology indications. Dr Ordentlich spent five years as a research scientist leading multiple lead discovery and optimization projects at X-Ceptor Therapeutics, which was acquired by Exelixis in 2004.In 2005 Dr Ordentlich co-founded Syndax Pharmaceuticals, a NASDAQ-listed, clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies with three clinical stage assets, where he is currently the Chief Scientific Officer.

Dr. Allen Ebens has more than 25 years of industry research and drug development experience focused in the areas of oncology, hematology, hematology/oncology, and immunology.He has worked in a variety of therapeutic platforms including small molecule discovery, conventional antibody therapies, antibody-drug conjugates, T-cell recruiting bispecific antibodies and CAR-T and TCR-based cellular therapies. Dr. Ebens started his professional career at Exelixis and went on to work at Genentech, Juno, NGM Bio, and is currently Chief Scientific Officer at Vera Therapeutics.Over the course of his career he has invented and developed or made very substantial contributions to more than a dozen molecules that have gone on to clinical testing, including polatuzumab vedotin, an ADC which was approved for use in lymphoma patients by the FDA in 2019.

The uniqueness that Patry’s holds in the Development of the first antibody drug that could treat brain cancer, with the therapy able to cross the blood-brain barrier in a major feat for science.
Dr Campbell says DNA damage repair and blood-brain barrier therapeutics are high on big pharma’s shopping list, as is anything that targets the most problematic cancers.
Dr Campbell says “No one else is developing this sort of cell-penetrating antibody as a cancer therapy.” Patrys’s first-in-class lead candidate to emerge from the Deoxymab platform is PAT-DX1.
I’ll also point out Herceptin which is the leading antibody drug on the market which Pamela Klein and Suzy Jones were part of the team leading that from Genentech. In 2019 Herceptins sales reached 6.08 BILLION DOLLARS.